BIOHEART-B (02185) surged nearly 10% again, rising 9.94% to HK$7.85 as of press time, with a turnover of HK$11.76 million. On the news front, Lanfan Medical previously announced that Lanfan Biosensors leveraged its platform capabilities and industry reputation in overseas markets to quickly reach an "overseas expansion" cooperation agreement with BIOHEART regarding its Iberis™ multi-electrode renal denervation (RDN) system. The system has already completed commercial deployment in Germany, Spain, Italy and other countries, with Germany and France having included it in their medical insurance coverage. A research report indicates that percutaneous renal denervation (RDN) represents a new device-based therapy for uncontrolled and resistant hypertension. According to consulting data, the Chinese RDN annual market size is expected to exceed 10 billion RMB by 2032. The report points out that BIOHEART's Iberis RDN system is the only globally approved system that can perform RDN through both transradial (TRA) and transfemoral approaches, demonstrating significant first-mover advantage. Domestically, the company has reached major strategic partnerships with Yuanda Health, while internationally it has partnered with Lanfan Biosensors across multiple countries and regions. With Germany and France having included Iberis RDN in medical insurance coverage, this currently represents the starting point for BIOHEART's accelerated commercialization, warranting attention to the company's development.